DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
RECOMBINANT HUMAN KALLIKREIN-1
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus; Kidney Diseases
Unknown
RECOMBINANT HUMAN KALLIKREIN-1
×
Maximum Phase:
2
First Approval:
None
UNII:
M5EX3P489F
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVDORALIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Pemphigoid, Bullous; Severe Acute Respiratory Syndrome
C5a anaphylatoxin chemotactic receptor inhibitor
AVDORALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
DW4CE8MKS9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PZ-128
2
Protein
Investigational
Unknown
Unknown
Coronary Disease
Proteinase-activated receptor 1 inhibitor
PZ-128
×
Maximum Phase:
2
First Approval:
None
UNII:
IYT6MP4NS9
Molecule Type:
Protein
Molecular Formula:
C55H99N13O9
Molecular Weight:
1086.48
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
POLAPREZINC
2
Small molecule
Investigational
Unknown
Unknown
Peripheral Arterial Disease; Persian Gulf Syndrome; Schizophrenia
Unknown
POLAPREZINC
×
Maximum Phase:
2
First Approval:
None
UNII:
8HO6PVN24W
Molecule Type:
Small molecule
Molecular Formula:
C9H14N4O3
Molecular Weight:
226.24
AlogP:
-1.13
PSA:
121.1
HBD:
4.0
HBA:
#RotB:
6.0
Source:
JNJ-40411813
2
Small molecule
Investigational
Unknown
Unknown
Perceptual Disorders; Depressive Disorder, Major; Schizophrenia; Seizures
Metabotropic glutamate receptor 2 positive allosteric modulator
JNJ-40411813
×
Maximum Phase:
2
First Approval:
None
UNII:
612BYT76F3
Molecule Type:
Small molecule
Molecular Formula:
C20H25ClN2O
Molecular Weight:
344.89
AlogP:
4.69
PSA:
25.24
HBD:
0.0
HBA:
#RotB:
5.0
Source:
ALBITIAZOLIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ALBITIAZOLIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
HKM715W3UT
Molecule Type:
Small molecule
Molecular Formula:
C24H42N2O2S2+2
Molecular Weight:
454.75
AlogP:
4.67
PSA:
48.22
HBD:
2.0
HBA:
#RotB:
17.0
Source:
EZLOPITANT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Neurokinin 1 receptor antagonist
EZLOPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
3L098A8MPY
Molecule Type:
Small molecule
Molecular Formula:
C31H38N2O
Molecular Weight:
454.66
AlogP:
6.2
PSA:
24.5
HBD:
1.0
HBA:
#RotB:
8.0
Source:
SILIBININ
2
Small molecule
Investigational
Unknown
Unknown
Tobacco Use Disorder; Hepatitis C; Liver Failure; Prostatic Neoplasms, Castration-Resistant
Unknown
SILIBININ
×
Maximum Phase:
2
First Approval:
None
UNII:
4RKY41TBTF
Molecule Type:
Small molecule
Molecular Formula:
C25H22O10
Molecular Weight:
482.44
AlogP:
2.36
PSA:
155.14
HBD:
5.0
HBA:
#RotB:
4.0
Source:
AB1010
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AB1010
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIPOIC ACID
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
LIPOIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MBL-HCV-1
2
Antibody
Investigational
Unknown
Unknown
Hepatitis C
Genome polyprotein inhibitor
MBL-HCV-1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-337
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Sarcoma, Clear Cell; Stomach Neoplasms
Hepatocyte growth factor receptor inhibitor
AMG-337
×
Maximum Phase:
2
First Approval:
None
UNII:
08WG8S0L8D
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STRONTIUM
2
Small molecule
Investigational
Unknown
Unknown
Osteoporosis
Unknown
STRONTIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
YZS2RPE8LE
Molecule Type:
Small molecule
Molecular Formula:
H2Sr
Molecular Weight:
89.64
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MVT-5873
2
Unknown
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Sialyl Lewis A (CA19-9) binding agent
MVT-5873
×
Maximum Phase:
2
First Approval:
None
UNII:
KEX1QY18OH
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DIMIRACETAM
2
Small molecule
Investigational
Unknown
Unknown
Acquired Immunodeficiency Syndrome
Unknown
DIMIRACETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
4AW7F70MZO
Molecule Type:
Small molecule
Molecular Formula:
C6H8N2O2
Molecular Weight:
140.14
AlogP:
-0.94
PSA:
49.41
HBD:
1.0
HBA:
#RotB:
0.0
Source:
GARETOSMAB
2
Antibody
Investigational
Unknown
Unknown
Myositis, Inclusion Body; Myositis Ossificans
Inhibin beta A chain inhibitor
GARETOSMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
KR9ZSKO5QE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REVEXEPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Gastroesophageal Reflux
Serotonin 4 (5-HT4) receptor agonist
REVEXEPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
8C63R2Y02M
Molecule Type:
Small molecule
Molecular Formula:
C21H32ClN3O4
Molecular Weight:
425.96
AlogP:
2.08
PSA:
97.05
HBD:
3.0
HBA:
#RotB:
7.0
Source:
GEDATOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
PI3-kinase class I inhibitor
GEDATOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
96265TNH2R
Molecule Type:
Small molecule
Molecular Formula:
C32H41N9O4
Molecular Weight:
615.74
AlogP:
3.02
PSA:
128.29
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LABRADIMIL
2
Protein
Investigational
Unknown
Unknown
Glioma; Medulloblastoma; Meningitis, Cryptococcal; Central Nervous System Neoplasms
Bradykinin B2 receptor agonist
LABRADIMIL
×
Maximum Phase:
2
First Approval:
None
UNII:
2MK663C346
Molecule Type:
Protein
Molecular Formula:
C49H75N15O12S
Molecular Weight:
1098.3
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GHRP-1
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GHRP-1
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2623091
2
Small molecule
Investigational
Unknown
Unknown
Essential Hypertension; Renal Insufficiency, Chronic
Mineralocorticoid receptor antagonist
LY2623091
×
Maximum Phase:
2
First Approval:
None
UNII:
6FHZ595FNM
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLEMBATUMUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell; Breast Neoplasms; Melanoma; Osteosarcoma
Transmembrane glycoprotein NMB binding agent
GLEMBATUMUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
1568H6A58U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMONAFIDE DIHYDROCHLORIDE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AMONAFIDE DIHYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAL
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; HIV Infections
Parathyroid hormone-related protein inhibitor
CAL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1512
2
Antibody
Investigational
Unknown
Unknown
Unknown
P-selectin inhibitor
RG-1512
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAS-108
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TAS-108
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PHENCYNONATE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Motion Sickness
Unknown
PHENCYNONATE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
54F576E38V
Molecule Type:
Small molecule
Molecular Formula:
C22H32ClNO3
Molecular Weight:
393.96
AlogP:
3.34
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
4.0
Source:
COTADUTIDE
2
Protein
Investigational
Unknown
Unknown
Obesity; Renal Insufficiency; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease
Glucagon-like peptide 1 receptor agonist
COTADUTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
QL6A9B13HW
Molecule Type:
Protein
Molecular Formula:
C167H252N42O55
Molecular Weight:
3728.09
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
NRX-101
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NRX-101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAY1067197
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Adenosine A1 receptor agonist
BAY1067197
×
Maximum Phase:
2
First Approval:
None
UNII:
IV690462VZ
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUVADAXISTAT
2
Small molecule
Investigational
Unknown
Unknown
Friedreich Ataxia; Schizophrenia
Unknown
LUVADAXISTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
76IC00YRVR
Molecule Type:
Small molecule
Molecular Formula:
C13H11F3N2O2
Molecular Weight:
284.24
AlogP:
2.28
PSA:
65.98
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ERITORAN
2
Small molecule
Investigational
Unknown
Unknown
Insulin Resistance
Unknown
ERITORAN
×
Maximum Phase:
2
First Approval:
None
UNII:
551541VI0Y
Molecule Type:
Small molecule
Molecular Formula:
C66H126N2O19P2
Molecular Weight:
1313.68
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CL-184
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
CL-184
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZD-1480
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Primary Myelofibrosis; Stomach Neoplasms; Thrombocythemia, Essential
Tyrosine-protein kinase JAK2 inhibitor
AZD-1480
×
Maximum Phase:
2
First Approval:
None
UNII:
KL2Z2TLF01
Molecule Type:
Small molecule
Molecular Formula:
C14H14ClFN8
Molecular Weight:
348.77
AlogP:
3.01
PSA:
104.3
HBD:
3.0
HBA:
#RotB:
5.0
Source:
LITGENPROSTUCEL-L
2
Cell
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Unknown
LITGENPROSTUCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
181
182
183
184
185
186
187
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA